Compare SE & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SE | TAK |
|---|---|---|
| Founded | 2009 | 1781 |
| Country | Singapore | Japan |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.9B | 57.6B |
| IPO Year | 2017 | 2007 |
| Metric | SE | TAK |
|---|---|---|
| Price | $95.19 | $17.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 29 | 3 |
| Target Price | ★ $156.65 | $22.07 |
| AVG Volume (30 Days) | ★ 2.5M | 2.0M |
| Earning Date | 11-10-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 2.71% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.78 | $4.39 |
| Revenue Next Year | $22.80 | $1.93 |
| P/E Ratio | $49.15 | ★ $41.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $77.05 | $12.99 |
| 52 Week High | $193.48 | $19.10 |
| Indicator | SE | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 29.63 | 43.49 |
| Support Level | $81.51 | $17.95 |
| Resistance Level | $98.89 | $18.91 |
| Average True Range (ATR) | 2.95 | 0.19 |
| MACD | -0.69 | -0.11 |
| Stochastic Oscillator | 0.95 | 1.46 |
Sea started as a gaming business, Garena, but in 2015 expanded into e-commerce. Sea operates Southeast Asia's largest e-commerce company, Shopee, in terms of gross merchandise value. Shopee is a hybrid consumer-to-consumer and business-to-consumer marketplace platform operating in Indonesia, Taiwan, Vietnam, Thailand, Malaysia, the Philippines, and Brazil. For Garena, Free Fire is the key revenue-generating game. Sea's third business, Monee, provides lending, payment, digital banking, and insurance services. As of March 2025, Forrest Li, the founder, chair, and CEO, owned 59.1% of the voting power. Tencent owned 18.5% of issued shares with no voting power.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.